Your browser is no longer supported. Please, upgrade your browser.
Settings
REGN [NASD]
Regeneron Pharmaceuticals, Inc.
IndexS&P 500 P/E14.77 EPS (ttm)30.68 Insider Own1.30% Shs Outstand105.50M Perf Week-5.00%
Market Cap49.24B Forward P/E11.31 EPS next Y40.07 Insider Trans-10.12% Shs Float102.23M Perf Month-16.71%
Income3.51B PEG1.33 EPS next Q9.57 Inst Own89.10% Short Float2.07% Perf Quarter-13.45%
Sales8.50B P/S5.79 EPS this Y65.30% Inst Trans0.31% Short Ratio2.05 Perf Half Y-25.77%
Book/sh104.51 P/B4.34 EPS next Y-8.23% ROA22.20% Target Price650.88 Perf Year-1.03%
Cash/sh33.01 P/C13.73 EPS next 5Y11.11% ROE33.20% 52W Range418.01 - 664.64 Perf YTD-6.19%
Dividend- P/FCF24.58 EPS past 5Y40.80% ROI23.90% 52W High-31.81% Beta0.13
Dividend %- Quick Ratio3.10 Sales past 5Y15.70% Gross Margin86.80% 52W Low8.42% ATR14.16
Employees9123 Current Ratio3.60 Sales Q/Q11.70% Oper. Margin42.10% RSI (14)28.56 Volatility3.15% 2.92%
OptionableYes Debt/Eq0.00 EPS Q/Q47.90% Profit Margin41.30% Rel Volume1.09 Prev Close458.60
ShortableYes LT Debt/Eq0.24 EarningsFeb 05 BMO Payout0.00% Avg Volume1.03M Price453.19
Recom2.00 SMA20-7.25% SMA50-8.77% SMA200-19.56% Volume1,124,835 Change-1.18%
Jan-25-21Upgrade BMO Capital Markets Market Perform → Outperform $630
Jan-13-21Upgrade The Benchmark Company Hold → Buy $590
Jan-08-21Upgrade Citigroup Neutral → Buy $635 → $575
Oct-05-20Upgrade Cantor Fitzgerald Neutral → Overweight $690
Aug-20-20Downgrade The Benchmark Company Buy → Hold
Jul-09-20Upgrade SunTrust Hold → Buy $400 → $750
May-26-20Upgrade Wells Fargo Equal Weight → Overweight $559 → $734
Apr-28-20Downgrade Citigroup Buy → Neutral $540 → $575
Apr-17-20Upgrade The Benchmark Company Hold → Buy $655
Apr-08-20Initiated The Benchmark Company Hold
Mar-31-20Initiated Wolfe Research Peer Perform
Feb-27-20Initiated Barclays Overweight $530
Feb-26-20Upgrade Canaccord Genuity Hold → Buy $550
Feb-26-20Downgrade Robert W. Baird Outperform → Neutral $410
Feb-25-20Upgrade Jefferies Hold → Buy $355 → $492
Feb-11-20Upgrade Argus Hold → Buy $430
Dec-24-19Initiated Raymond James Mkt Perform
Dec-16-19Downgrade Evercore ISI Outperform → In-line
Dec-13-19Upgrade Credit Suisse Neutral → Outperform $400
Nov-12-19Initiated SunTrust Hold $360
Feb-25-21 02:39PM  
02:13PM  
11:26AM  
10:35AM  
08:57AM  
07:16AM  
07:06AM  
07:00AM  
Feb-24-21 01:52PM  
Feb-23-21 07:37AM  
07:17AM  
06:50AM  
Feb-22-21 01:00PM  
Feb-20-21 09:22AM  
Feb-17-21 11:40AM  
Feb-16-21 06:55AM  
Feb-15-21 12:44AM  
Feb-14-21 09:05AM  
08:10AM  
Feb-12-21 04:15PM  
12:16PM  
09:35AM  
08:20AM  
07:30AM  
04:51AM  
01:00AM  
Feb-11-21 05:04PM  
02:00PM  
09:13AM  
06:14AM  
Feb-10-21 11:57AM  
10:06AM  
06:25AM  
05:24AM  
04:13AM  
Feb-09-21 05:22PM  
Feb-05-21 05:30PM  
04:33PM  
02:01PM  
01:45PM  
12:00PM  
11:05AM  
10:54AM  
10:16AM  
10:04AM  
09:45AM  
08:09AM  
07:55AM  
07:55AM  
07:05AM  
06:46AM  
06:30AM  
06:30AM  
03:35AM  
12:01AM  
Feb-04-21 07:00PM  
11:30AM  
Feb-02-21 09:48AM  
Feb-01-21 05:50PM  
11:25AM  
09:59AM  
Jan-31-21 05:22AM  
Jan-29-21 12:02PM  
11:16AM  
08:32AM  
Jan-28-21 12:56PM  
10:05AM  
07:04AM  
06:15AM  
Jan-27-21 03:20PM  
11:10AM  
11:05AM  
07:51AM  
07:35AM  
07:00AM  
06:33AM  
06:00AM  
Jan-26-21 05:50PM  
01:35PM  
10:22AM  
10:10AM  
09:37AM  
09:00AM  
08:45AM  
08:24AM  
07:00AM  
07:00AM  
Jan-25-21 12:32PM  
11:15AM  
09:50AM  
09:30AM  
Jan-22-21 08:06AM  
Jan-21-21 12:01PM  
09:29AM  
Jan-19-21 04:15PM  
Jan-14-21 12:10PM  
Jan-13-21 04:27PM  
02:53PM  
02:29PM  
02:17PM  
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma in adults and adolescents; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it offers Inmazeb injection for infection caused by Zaire ebolavirus; and develops product candidates for treating patients with eye, allergic and inflammatory, cancer, cardiovascular and metabolic, pain, infectious, and other diseases. The company has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services. It has collaborations with Zai Lab Limited; Intellia Therapeutics, Inc.; and Biomedical Advanced Research Development Authority. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
VAGELOS P ROYDirectorFeb 23Option Exercise52.03250,00013,007,500487,088Feb 24 04:02 PM
RYAN ARTHUR FDirectorFeb 01Sale506.9210050,69223,691Feb 02 04:06 PM
BROWN MICHAEL SDirectorJan 25Option Exercise380.952,480944,7563,371Jan 27 04:06 PM
BROWN MICHAEL SDirectorJan 25Sale554.322,4801,374,714891Jan 27 04:06 PM
RYAN ARTHUR FDirectorJan 04Sale483.6010048,36023,543Jan 05 04:09 PM
YANCOPOULOS GEORGEPresident and Chief ScientificDec 30Option Exercise52.03398,07920,712,050908,303Dec 31 05:30 PM
RYAN ARTHUR FDirectorDec 01Sale520.4810052,04823,643Dec 02 04:09 PM
MURPHY ANDREW JEVP ResearchNov 17Sale542.736,6283,597,18847,136Nov 18 04:02 PM
MURPHY ANDREW JEVP ResearchNov 16Option Exercise30.6313,736420,73460,872Nov 18 04:02 PM
COLES N ANTHONYDirectorNov 13Option Exercise345.47113,800654Nov 13 05:57 PM
RYAN ARTHUR FDirectorNov 02Sale548.5410054,85423,743Nov 03 05:22 PM
MURPHY ANDREW JEVP ResearchOct 22Option Exercise38.565,185199,92647,136Oct 23 04:02 PM
McCourt MarionSVP CommercialOct 05Option Exercise342.931,000342,93014,963Oct 06 04:07 PM
GOLDSTEIN JOSEPH LDirectorOct 05Option Exercise520.019,2124,790,33214,855Oct 06 04:09 PM
McCourt MarionSVP CommercialOct 05Sale600.001,000600,00013,963Oct 06 04:07 PM
GOLDSTEIN JOSEPH LDirectorOct 05Sale600.009,2125,527,2005,643Oct 06 04:09 PM
RYAN ARTHUR FDirectorOct 01Sale558.1310055,81328,343Oct 05 04:13 PM
BROWN MICHAEL SDirectorSep 22Option Exercise378.775,0901,927,9175,733Sep 23 04:01 PM
BROWN MICHAEL SDirectorSep 22Sale552.361,000552,3609,349Sep 23 04:01 PM
BROWN MICHAEL SDirectorSep 22Sale552.365,0902,811,512643Sep 23 04:01 PM
GOLDSTEIN JOSEPH LDirectorSep 22Sale552.362011,0475,643Sep 23 04:00 PM
GOLDSTEIN JOSEPH LDirectorSep 21Option Exercise376.7616,5746,244,37222,217Sep 23 04:00 PM
GOLDSTEIN JOSEPH LDirectorSep 21Sale549.8616,5549,102,4465,663Sep 23 04:00 PM
RYAN ARTHUR FDirectorSep 01Sale604.5810060,45828,443Sep 03 04:18 PM
LAROSA JOSEPH JEVP General Counsel and SecretAug 31Sale615.044,6722,873,46714,438Aug 31 04:37 PM
SING GEORGE LDirectorAug 31Sale612.0610,0006,120,55554,415Aug 31 04:36 PM
POON CHRISTINE ADirectorAug 28Option Exercise28.4440,0001,137,55041,433Aug 31 04:35 PM
POON CHRISTINE ADirectorAug 28Sale601.2240,00024,048,7151,433Aug 31 04:35 PM
LAROSA JOSEPH JEVP General Counsel and SecretAug 27Option Exercise52.0310,000520,30021,241Aug 31 04:37 PM
SING GEORGE LDirectorAug 25Option Exercise273.6712,7503,489,29397,165Aug 27 04:23 PM
Van Plew Daniel PEVP & General Mgr Industrial OAug 25Sale610.8927,10916,560,73820,001Aug 27 04:21 PM
SING GEORGE LDirectorAug 25Sale612.001,000612,0003,700Aug 27 04:23 PM
SING GEORGE LDirectorAug 25Sale607.2832,75019,888,51864,415Aug 27 04:23 PM
SING GEORGE LDirectorAug 24Option Exercise177.8210,0371,784,779104,452Aug 24 06:13 PM
SING GEORGE LDirectorAug 24Sale593.6320,03711,894,57784,415Aug 24 06:13 PM
SING GEORGE LDirectorAug 21Option Exercise117.249,9631,168,071114,078Aug 24 06:13 PM
SING GEORGE LDirectorAug 21Sale605.1219,96312,080,04094,415Aug 24 06:13 PM
GOLDSTEIN JOSEPH LDirectorAug 21Sale617.181,000617,1805,643Aug 24 05:19 PM
SING GEORGE LDirectorAug 20Option Exercise57.1110,000571,100114,415Aug 24 06:13 PM
Van Plew Daniel PEVP & General Mgr Industrial OAug 20Option Exercise179.1375,00013,434,75095,001Aug 24 04:47 PM
McCourt MarionSVP CommercialAug 20Option Exercise342.931,000342,93014,963Oct 06 04:07 PM
SING GEORGE LDirectorAug 20Sale616.9121,00012,955,042104,415Aug 24 06:13 PM
McCourt MarionSVP CommercialAug 20Sale612.151,000612,15013,963Oct 06 04:07 PM
VAGELOS P ROYDirectorAug 11Sale602.9433,46020,174,35550,192Aug 13 04:02 PM
Landry Robert EEVP Finance CFOAug 04Sale654.46696455,50423,973Aug 05 05:07 PM
RYAN ARTHUR FDirectorAug 03Sale641.9310064,19328,543Aug 05 05:09 PM
Landry Robert EEVP Finance CFOJul 21Sale647.58391253,20424,669Jul 22 04:30 PM
Fenimore Christopher R.VP ControllerJul 21Sale642.043,7092,381,31717,501Jul 22 04:31 PM
Fenimore Christopher R.VP ControllerJul 20Option Exercise156.0112,2241,907,01525,277Jul 22 04:31 PM
Landry Robert EEVP Finance CFOJul 20Option Exercise491.438,5004,177,16029,671Jul 22 04:30 PM
Landry Robert EEVP Finance CFOJul 14Sale640.50579370,85023,973Jul 14 04:17 PM
MURPHY ANDREW JEVP ResearchJul 14Sale633.482,3801,507,67741,951Jul 15 04:51 PM
MURPHY ANDREW JEVP ResearchJul 14Sale623.893,9292,451,27744,331Jul 15 04:51 PM
MURPHY ANDREW JEVP ResearchJul 13Option Exercise30.6313,000398,19054,951Jul 15 04:51 PM
MURPHY ANDREW JEVP ResearchJul 13Sale628.508,0005,028,02241,951Jul 15 04:51 PM
Landry Robert EEVP Finance CFOJul 09Option Exercise399.663,0001,198,98026,973Jul 13 04:28 PM
Landry Robert EEVP Finance CFOJul 08Sale639.661,160742,01123,973Jul 09 04:29 PM
SING GEORGE LDirectorJul 07Option Exercise33.427,500250,650122,915Jul 08 04:16 PM
Zoghbi Huda YDirectorJul 07Option Exercise391.921,706668,6162,349Jul 08 04:14 PM
Landry Robert EEVP Finance CFOJul 07Option Exercise524.4712,5006,555,85033,973Jul 09 04:29 PM
Zoghbi Huda YDirectorJul 07Sale650.001,7061,108,900643Jul 08 04:14 PM
SING GEORGE LDirectorJul 07Sale650.163,0001,950,474400Jul 08 04:16 PM
SING GEORGE LDirectorJul 07Sale650.007,5004,875,000115,415Jul 08 04:16 PM
BROWN MICHAEL SDirectorJul 01Option Exercise413.333,6131,493,3614,256Jul 02 04:02 PM
BROWN MICHAEL SDirectorJul 01Sale607.623,6132,195,342643Jul 02 04:02 PM
RYAN ARTHUR FDirectorJul 01Sale609.7010060,97028,643Jul 02 04:01 PM
SING GEORGE LDirectorJun 29Sale608.913,0001,826,7211,400Jun 29 04:08 PM
Landry Robert EEVP Finance CFOJun 29Sale612.57400245,02923,973Jun 30 04:02 PM
Landry Robert EEVP Finance CFOJun 23Sale631.27512323,21224,373Jun 24 04:03 PM
Landry Robert EEVP Finance CFOJun 22Option Exercise555.678,9004,945,46333,273Jun 24 04:03 PM
Bassler Bonnie LDirectorJun 19Option Exercise391.922,5591,002,9233,202Jun 22 04:18 PM
Bassler Bonnie LDirectorJun 19Sale630.022,5591,612,211643Jun 22 04:18 PM
Fenimore Christopher R.VP ControllerJun 16Sale590.893,5562,101,21515,277Jun 17 04:02 PM
Fenimore Christopher R.VP ControllerJun 15Option Exercise47.079,406442,74220,323Jun 17 04:02 PM
Zoghbi Huda YDirectorJun 11Option Exercise391.921,706668,6162,349Jun 12 04:03 PM
Zoghbi Huda YDirectorJun 11Sale625.001,7061,066,250643Jun 12 04:03 PM
Landry Robert EEVP Finance CFOJun 11Sale612.08988604,73124,373Jun 12 04:01 PM
Landry Robert EEVP Finance CFOJun 10Option Exercise272.703,500954,45027,873Jun 12 04:01 PM
Zoghbi Huda YDirectorJun 10Option Exercise391.921,706668,6162,349Jun 12 04:03 PM
Zoghbi Huda YDirectorJun 10Sale610.241,7061,041,068643Jun 12 04:03 PM
Landry Robert EEVP Finance CFOJun 09Sale608.014,2712,596,79224,373Jun 10 04:04 PM
GOLDSTEIN JOSEPH LDirectorJun 08Option Exercise413.3310,8384,479,67117,481Jun 09 04:05 PM
Landry Robert EEVP Finance CFOJun 08Option Exercise272.7015,5004,226,85029,860Jun 10 04:04 PM
GOLDSTEIN JOSEPH LDirectorJun 08Sale592.9510,8386,426,3626,643Jun 09 04:05 PM
Bassler Bonnie LDirectorJun 05Option Exercise391.922,5591,002,9233,202Jun 05 04:15 PM
Bassler Bonnie LDirectorJun 05Sale600.002,5591,535,400643Jun 05 04:15 PM
RYAN ARTHUR FDirectorJun 01Sale603.2310060,32328,743Jun 02 04:04 PM
SING GEORGE LDirectorMay 29Sale596.511,000596,5102,400Jun 01 04:08 PM
GOLDSTEIN JOSEPH LDirectorMay 28Sale578.941,000578,9406,643Jun 01 04:02 PM
SING GEORGE LDirectorMay 28Sale579.001,000579,0002,900Jun 01 04:08 PM
VAGELOS P ROYChairman of the BoardMay 21Sale577.49783452,178307,749May 22 06:21 PM
VAGELOS P ROYChairman of the BoardMay 21Sale564.37148,81183,984,786308,532May 22 06:21 PM
VAGELOS P ROYChairman of the BoardMay 20Option Exercise30.63312,5009,571,875497,063May 22 06:21 PM
LAROSA JOSEPH JEVP General Counsel and SecretMay 15Sale572.008,3804,793,36014,438May 15 04:03 PM
LAROSA JOSEPH JEVP General Counsel and SecretMay 14Option Exercise59.2018,3111,084,01132,749May 15 04:03 PM
SING GEORGE LDirectorMay 13Option Exercise33.425,000167,100120,415May 13 09:00 PM
SING GEORGE LDirectorMay 13Sale580.005,0002,900,000115,415May 13 09:00 PM
SCHLEIFER LEONARD SPresident & CEOMay 12Sale569.22150,92285,908,042474,499May 13 09:01 PM
SCHLEIFER LEONARD SPresident & CEOMay 11Option Exercise30.63312,5009,571,875722,368May 13 09:01 PM
SING GEORGE LDirectorMay 11Sale575.00850488,7502,150May 13 09:00 PM